PrimaryBid.com Offer

RNS Number : 6758N

Tissue Regenix Group PLC

21 May 2020

 

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF TISSUE REGENIX GROUP PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021).

21 May 2020

Tissue Regenix Group plc 

("Tissue Regenix", the "Group" or the "Company") ( AIM : TRX )

PrimaryBid.com Offer

Tissue Regenix Group Plc ( AIM : TRX ), a leading regenerative medicine company, is pleased to announce, a conditional offer for subscription via PrimaryBid (the "PrimaryBidOffer") of new ordinary shares ("New Ordinary Shares") at an issue price of 0.25 pence per New Ordinary Share (the "Issue Price"), being a discount of  76   per cent to the closing mid-price on 20 May 2020. The Company is also conducting a placing of new Ordinary Shares at the Issue Price by way of an accelerated bookbuild process by Stifel Nicolaus Europe Limited   and Allenby Capital Limited, acting as sub-placing agent, (the "Placing") as announced on 21 May 2020.

The PrimaryBid Offer and the Placing are conditional on the new Ordinary Shares to be issued pursuant to the PrimaryBid Offer and the Placing being admitted to trading on London Stock Exchange ("Admission"). Admission is expected to be take place at 8.00 a.m. on or around 10 June 2020, and that dealings in the New Ordinary Shares will commence at that time, and in any event no later than 30 June 2020. The PrimaryBid Offer will not be completed without the Placing also being completed and is conditional on, inter alia, the passing of the Placing Resolutions to be proposed at a General Meeting expected to be held at the Company's offices of Squire Patton Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 pm on 9 June 2020, as well as the successful capital reorganisation of the Company. 

The Company will use the funds raised to fund the Group's manufacturing capacity expansion programme in the US, commencing immediately, and for general working capital purposes.

For more information about the Company, please visit the Issuer Services Page, a service provided by London Stock Exchange, at https://profile.lsegissuerservices.com/TissueRegenixGroup/overview .

PrimaryBid Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the PrimaryBid Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play. PrimaryBid does not charge investors any commission for this service.

The PrimaryBid Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors from 4.35 p.m. on 21^st May 2020 to 9 p.m. on 21^st May 2020 . The PrimaryBid Offer may close early if it is oversubscribed.

Subscriptions under the PrimaryBid Offer will be considered by the Company on a "first come, first served" basis, subject to conditions which are available to view on PrimaryBid.com.

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Offer without giving any reason for such rejection.

No commission is charged to investors on applications to participate in the PrimaryBid Offer made through PrimaryBid.  It is vital to note that once an application for New Ordinary Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the PrimaryBid Offer, visit  www.PrimaryBid.com  or call PrimaryBid.com on [phone]. 

The New Ordinary Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

Tissue Regenix Group plc Caitlin Pearson, Head of Communications	+ 44 (0) 330 430 3073 / + 44 (0) 7920272441
PrimaryBid Limited Kieran D'Silva / James Deal	+ 44 (0) 203 026 4750
Stifel Nicolaus Europe Limited Jonathan Senior/Alex Price/Ben Maddison	+ 44 (0) 207 710 7600
FTI Consulting  Simon Conway / Victoria Foster Mitchell / Mary Whittow	+ 44 (0) 203 727 1000

Details of the Offer

The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com.

The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority. The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.

There is a minimum subscription of £100 per investor under the terms of the Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis.

For further details please refer to the PrimaryBid.com website at  www.PrimaryBid.com . The terms and conditions on which the Offer is made, including the procedure for application and payment for New Ordinary Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for New Ordinary Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for New Ordinary Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the New Ordinary Shares if they are in any doubt. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com .

END

 

END

 

 

IOEABMATMTITBIM